News

A committee of the European Medicines Agency has recommended Enjaymo (sutimlimab-jome) be approved for hemolytic anemia, or anemia due to the destruction of red blood cells, in adults with cold agglutinin disease (CAD). The positive opinion from the agency’s Committee for Medicinal Products for Human Use now will…

Global Genes announced the winners of its RARE Champions of Hope awards, recognizing leaders and organizations for their work driving advocacy and innovation in rare diseases, such as cold agglutinin disease (CAD). As part of the 2022 RARE Disease Patient Advocacy Summit, held Sept. 12–14 in San Diego,…

Enjaymo (sutimlimab-jome) eased anemia, and reduced fatigue and the need for blood transfusions and other treatments in people with cold agglutinin disease (CAD) who hadn’t received blood transfusions recently, final results from the Phase 3 CADENZA trial show. Results were detailed in the study, “Sutimlimab in patients…

Either a hot water bath or a blood warmer attached to an infusion pump may be used to warm up blood donated from patients with cold agglutinin disease (CAD) in order to minimize the risk of agglutination, or blood cell clumping, in a subsequent stem cell transplant, a study…

Enjaymo (sutimlimab-jome) led to clinically relevant reductions in fatigue and improvements in quality of life in adults with primary cold agglutinin disease (CAD), according to additional six-month data from Part A of the Phase 3 CARDINAL trial. These benefits in several patient-reported outcomes add to previously reported data…

Fatigue is one of the most common symptoms of cold agglutinin disease (CAD), affecting 90% of patients, a U.S. survey found. Nearly half of people with the rare autoimmune disorder who responded to the survey, on the disease burden imposed by CAD, reported experiencing fatigue on a daily basis.

Patients who develop cold agglutinin antibodies after COVID-19 infection won’t always show overt signs of cold agglutinin disease (CAD), a case report suggested. Two patients with COVID-19 at a clinic in Japan had high levels of the antibodies, but didn’t show signs of red blood cell destruction (hemolytic anemia)…

A total of 30 patient advocacy groups working to further understanding and the needs of people living with rare diseases have been selected to receive a Horizon Therapeutics‘ #RAREis Global Advocate Grant. Winners of this year’s inaugural awards are spread across nine countries and represent a total of 29 rare…

A test called Hevylite was superior to standard methods at detecting immunoglobulin M (IgM) — a type of antibody associated with cold agglutinin disease (CAD) — in the blood of people with the disease, a small study has shown. This suggests that Hevylite, sold by Binding Site,…

A man’s cold agglutinin disease (CAD) was caused by a type of blood cancer called B-lymphoblastic leukemia, according to a recent case report. While cancer is a known cause of CAD, this type of cancer was unexpected, the researchers noted, adding that a full work-up is needed to ensure…